Jiang Yingxue, Liu Taishan, Duan Zhiguang, Qu Linlin, Liu Lin, Fan Yanru, Zhu Chenhui, Ma Xiaoxuan
Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China.
Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China; Xi'an Giant Biotechnology Co. Ltd., Xi'an 710100, China.
Acta Biomater. 2025 Jul 5. doi: 10.1016/j.actbio.2025.07.014.
Bacterial infections, oxidative stress and inflammatory responses after tendon surgery are highly associated with peritendinous adhesion formation. Although drug-loaded anti-adhesion barriers have been extensively studied, most of them lack control over the process of drug release from the anti-adhesion barrier and fail to coordinate with the tendon's own biological mechanisms. Here, inspired by the mechanisms of tendon adhesion development, an anti-peritendon adhesion hydrated fibrous gene patch with antimicrobial antioxidant and anti-inflammatory activity was developed. First, hydrazinylated hyaluronic acid and dialdehyde polyethylene glycol were crosslinked to prepare a self-healing hydrogel (DHP). Then, the hydrogel loaded with transforming growth factor-β1 siRNA/TAT conjugate was attached to a Poly(L-lactide-co-ε-caprolactone) electrospun fiber membrane containing berberine to form a composite bilayer patch. The encapsulated TGF-β1 siRNA complex in the siRNA@DHP-PB patch responds to the microenvironment by releasing to the outer gel side, blocking the key fibrosis pathway and inhibiting the formation of tendon adhesion tissue; the loaded Ber is released to the inner fiber side, with antioxidant, anti-inflammatory and antimicrobial properties, providing a good microenvironment for tendon regeneration. This design fills the therapeutic gap between transient anti-inflammatory treatment and delayed antifibrotic intervention, offering a paradigm shift in the field of regenerative medicine that transcends tendon repair and holds potential for chronotherapeutic applications and multimodal anti-adhesion strategies. STATEMENT OF SIGNIFICANCE: Peritendinous adhesions are a critical post-tendon-injury complication. Conventional anti-adhesion barriers (e.g., drug-loaded hydrogels/fibers) lack microenvironment-responsive drug control and tendon-specific biointegration. We developed a multifunctional siRNA@DHP-PB patch with antimicrobial, antioxidant, and anti-inflammatory properties. Its outer layer is a self-healing hydrogel (crosslinked hydrazide-hyaluronic acid/aldehyde-polyglycol) encapsulating TGF-β1 siRNA/TAT, while the inner PLCL electrospun membrane is loaded with berberine. The siRNA complex is released toward the gel interface to suppress early-stage inflammatory TGF-β1, minimizing tendon toxicity. Berberine, released at the fiber interface, scavenges ROS, prevents infections, and inhibits oxidative damage. This bidirectional, biodegradable system enables targeted, adhesion-free tendon repair.
肌腱手术后的细菌感染、氧化应激和炎症反应与腱周粘连形成高度相关。尽管载药抗粘连屏障已得到广泛研究,但大多数缺乏对药物从抗粘连屏障释放过程的控制,且无法与肌腱自身的生物学机制协同作用。在此,受肌腱粘连发展机制的启发,开发了一种具有抗菌、抗氧化和抗炎活性的抗腱周粘连水合纤维基因贴片。首先,将肼基化透明质酸和二醛聚乙二醇交联制备自愈合水凝胶(DHP)。然后,将负载转化生长因子-β1 siRNA/TAT共轭物的水凝胶附着到含有黄连素的聚(L-丙交酯-共-ε-己内酯)电纺纤维膜上,形成复合双层贴片。siRNA@DHP-PB贴片中封装的TGF-β1 siRNA复合物通过向外层凝胶侧释放来响应微环境,阻断关键的纤维化途径并抑制肌腱粘连组织的形成;负载的黄连素释放到内层纤维侧,具有抗氧化、抗炎和抗菌特性,为肌腱再生提供良好的微环境。这种设计填补了瞬时抗炎治疗和延迟抗纤维化干预之间的治疗空白,为再生医学领域带来了范式转变,超越了肌腱修复,在时辰治疗应用和多模式抗粘连策略方面具有潜力。重要性声明:腱周粘连是肌腱损伤后的关键并发症。传统的抗粘连屏障(如载药水凝胶/纤维)缺乏对微环境响应的药物控制和肌腱特异性生物整合。我们开发了一种具有抗菌、抗氧化和抗炎特性的多功能siRNA@DHP-PB贴片。其外层是封装TGF-β1 siRNA/TAT的自愈合水凝胶(交联酰肼-透明质酸/醛-聚乙二醇),而内层PLCL电纺膜负载黄连素。siRNA复合物向凝胶界面释放以抑制早期炎症性TGF-β1,使肌腱毒性最小化。黄连素在纤维界面释放,清除活性氧,预防感染并抑制氧化损伤。这种双向、可生物降解的系统能够实现靶向、无粘连的肌腱修复。